Ebrahim Variava to Drug Monitoring
This is a "connection" page, showing publications Ebrahim Variava has written about Drug Monitoring.
Connection Strength
0,070
-
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019 03; 7(3):249-259.
Score: 0,039
-
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016 Apr; 71(4):1037-40.
Score: 0,031